+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID07399067

Phase 2 Study to Test the Safety and Effectiveness of IBI3002 Compared to Dupilumab and Placebo in Adults With Moderate to Severe Atopic Dermatitis

Led by Innovent Biologics (Suzhou) Co. Ltd. · Updated on 2026-02-13

120

Participants Needed

1

Research Sites

9 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating the efficacy and safety of IBI3002 in adults with moderate to severe Atopic Dermatitis AD. This Phase 2, multicenter, randomized, double-blind, placebo-controlled study includes about 120 participants who meet specific diagnostic criteria and disease severity measures. The study aims to assess how IBI3002 compares to placebo and dupilumab in improving skin condition and symptom measures related to AD. Participants will be randomly assigned to one of six groups receiving different doses of IBI3002, dupilumab, or matched placebo. All treatments are given by subcutaneous injection at specified intervals. The study includes multiple dose levels of IBI3002 and a loading dose of dupilumab followed by regular dosing. Treatment effects will be assessed over a 16-week period, with additional evaluations up to 20 weeks. During the study, participants will undergo blood collection, clinical assessments including the Eczema Area and Severity Index EASI, Investigators Global Assessment for AD, and symptom rating scales. Safety and tolerability will be monitored through reports of adverse events and pharmacokinetic testing. The primary outcome is the percentage change in EASI score at Week 16, with other measures including immunogenicity and pharmacodynamic effects. Participation involves regular visits and assessments through the treatment and follow-up periods.

CONDITIONS

Brief Title

A Proof-of-Concept Study of IBI3002 in Patients With Moderate to Severe Atopic Dermatitis

Research Team

M

Man Yang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here